An interventional study of 0.2mg Buprenorphine and Placebo in Depression, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-29.
Sponsored by University of Chicago · Not applicable, Interventional, and Basic science
This study seeks to to study the effects of buprenorphine, a partial mu-opioid agonist, on depressed mood in a healthy young adults with a range of depressive symptomatology.
It has been shown that opioid analgesics, particularly the mu-opioid partial agonist buprenorphine, have anti-depressant properties in laboratory animal models. In humans, rates of prescription opioid abuse are significantly higher in patients with depression. This suggests that individuals with negative mood states (e.g., depressive states) may respond more positively to opioid drugs. A handful of small studies in in humans have suggested that buprenorphine reduces symptoms of depression in patients who did not respond to standard anti-depressants, and laboratory studies have shown buprenorphine may reduce responses to some types of negative stimuli and enhance responses to positive stimuli. However, a controlled laboratory study assessing potential anti-depressant effects of an opioid medication has never been conducted. In this project, the investigators propose to examine depressive symptomatology as a predictor of subjective mood responses to buprenorphine, using two measures; i) self-reported depressive symptomatology as measured by the Beck Depression Inventory (BDI-II), and ii) physiological indices of depressive symptomatology as measured by heart rate variability. Reduced heart rate variability has been shown to be associated with depression, and such a physiological measure may allow for the detection of more subtle effects than would a self-report questionnaire alone. Healthy volunteers (N=60) will first complete the BDI and provide baseline measures of heart rate variability. Then they will attend two laboratory sessions, at which they will receive placebo or 0.2mg buprenorphine. The investigators have tested these low doses of buprenorphine in previous studies, and they produce measurable changes in mood and behavior in healthy volunteers. The investigators will collect measures of mood and physiological drug response (pupillometry, heart rate, and blood pressure) at regular intervals throughout each session, and will then examine their baseline indices of depressive symptomatology in relation to responses to the drug. The central hypothesis is that individuals with greater self-reported depressive symptoms and lower heart rate variability will experience the greatest enhancement of mood in response to buprenorphine. It is expected that this work will provide a better understanding of which individuals are most likely to experience positive mood effects in response to opioid drugs, and may therefore be at-risk for developing an opioid use disorder. Furthermore, it may lay the foundation for future research in the development of novel opioid-based treatments for depression.
Design: The study will use a 3-session within-subjects double-blind design in which participants will receive single doses of buprenorphine (0, 0.2 mg sublingual) in randomized order. All screening, orientation, and study session procedures will take place in the Human Behavioral Pharmacology Laboratory suite in the L4 wing of 5841 S. Maryland Ave.
Drug and Doses: Investigators will administer placebo, 0.2 mg buprenorphine (Temgesic) via sublingual tablet in counterbalanced order under double-blind conditions. These tablets dissolve within 5-8 minutes. This drug has been approved for treatment of severe pain. The onset of action after sublingual administration is 30 minutes, with a peak plasma concentration at 1/5-2 hours and a half-life of 5 hours. The dose of buprenorphine are very low, and the average maintenance dose for opioid abusers is 8 mg. Doses will be separated by at least 72 hours.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 38 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →University of Chicago is the lead sponsor of 907 studies on the registry; 182 are open to participants now.
Of its 99 completed or terminated interventional studies of FDA-regulated products, 68 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
Drug: 0.2mg Buprenorphine
Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
Drug: Placebo
Sublingual buprenorphine tablets (0.2mg)
Placebo
Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Subjective Response With and Without Buprenorphine
The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", and "Want More". The "Feel Drug", "Feel High", "Like Drug", and "Want More" subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.
Time frame: 0 through 3 hours after dosing.
| Milestone | Placebo, Then Buprenorphine | Buprenorphine, Then Placebo |
|---|---|---|
| Started | 19 | 19 |
| Completed | 19 | 19 |
| Not completed | 0 | 0 |
| Milestone | Placebo, Then Buprenorphine | Buprenorphine, Then Placebo |
|---|---|---|
| Started | 19 | 19 |
| Completed | 19 | 19 |
| Not completed | 0 | 0 |
| Milestone | Placebo, Then Buprenorphine | Buprenorphine, Then Placebo |
|---|---|---|
| Started | 19 | 19 |
| Completed | 19 | 19 |
| Not completed | 0 | 0 |
The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", and "Want More". The "Feel Drug", "Feel High", "Like Drug", and "Want More" subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.
| units on a scale | Low Dose Buprenorphine | Placebo |
|---|---|---|
| Feel Drug | 21.03 ± 3.32 | 10.64 ± 2.42 |
| Like Drug | 23.09 ± 3.97 | 19.8 ± 4.12 |
| Feel High | 10.91 ± 2.44 | 5.74 ± 1.62 |
| Want More | 17.46 ± 3.90 | 16.76 ± 3.86 |
Collected over 6 days for each intervention. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo, Then Buprenorphine | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Buprenorphine, Then Placebo | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Age, Categorical(Participants) | ALL Subjects |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 38 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | ALL Subjects |
|---|---|
| Female | 23 |
| Male | 15 |
| Race (NIH/OMB)(Participants) | ALL Subjects |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 7 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Chicago